MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.01
+0.18
+3.62%
Opening 13:01 02/24 EST
OPEN
4.990
PREV CLOSE
4.830
HIGH
5.06
LOW
4.900
VOLUME
466.44K
TURNOVER
--
52 WEEK HIGH
9.06
52 WEEK LOW
1.210
MARKET CAP
344.78M
P/E (TTM)
-5.3290
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Homozygous Familial Hypercholesterolemia Treatment Market Size, Growth, Share 2021, by Top Companies, Global Trends by Types and Application, Forecast to 2026
Feb 22, 2021 (The Expresswire) -- Global Homozygous Familial Hypercholesterolemia Treatment Market 2021 industry research report gives Advancement strategies...
The Express Wire · 1d ago
Glucose Dependent Insulinotropic Receptor Market Analysis, Recent Trends & Development, Top Company Profiles & Forecast 2020-2027 By Ameco Research
Comserve · 2d ago
Glucose Dependent Insulinotropic Receptor Market 2021: COVID-19 Impact, Growing Rapidly with Modern Trends, Development, Size, Share, Revenue, Demand and Forecast to 2027
Feb 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Glucose Dependent...
The Express Wire · 6d ago
Global Free Fatty Acid Receptor 4 Market Size, Share, Sales, Revenue 2021 Movements by Development Analysis, Progression Status, Revenue Expectation to 2027 | Research Report by Industry Research Biz
Feb 16, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Free Fatty Acid Receptor 4...
The Express Wire · 02/16 07:01
Hypertriglyceridemia Treatment Market 2021: Industry Analysis, Geographical Segmentation, Drivers, Challenges, Trends Forecasts By 2027
Feb 15, 2021 (The Expresswire) -- Global “Hypertriglyceridemia Treatment Market” forecast 2027; research report analyzed the existing state of the market by...
The Express Wire · 02/15 12:46
CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
NEWARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that manageme...
GlobeNewswire · 02/10 13:00
Global Primary Biliary Cirrhosis Drug Market Size 2021 Industry Share, Business Strategies, Growth Analysis, Regional Demand, Revenue, Key Manufacturers and 2025 Forecast Research Report
The Express Wire · 02/05 04:37
Tvardi Therapeutics Appoints Sujal Shah to Board of Directors
Tvardi Therapeutics ("Tvardi"), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Sujal Shah, Chief Executive Officer of CymaBay Therapeutics, to its Board of Direc...
BusinessWire · 01/28 21:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBAY. Analyze the recent business situations of CymaBay through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBAY stock price target is 13.09 with a high estimate of 20.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 242
Institutional Holdings: 69.31M
% Owned: 100.61%
Shares Outstanding: 68.89M
TypeInstitutionsShares
Increased
41
4.85M
New
64
-72.00K
Decreased
35
6.52M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.49%
Pharmaceuticals & Medical Research
+1.37%
Key Executives
Chairman/Independent Director
Robert Wills
President/Chief Executive Officer/Director/IR Contact Officer
Sujal Shah
Senior Vice President/Chief Scientific Officer
Charles McWherter
Chief Compliance Officer
Klara Dickinson
Vice President - Finance
Daniel Menold
Independent Director
Caroline Loewy
Independent Director
Paul Truex
Independent Director
Kurt von Emster
  • Dividends
  • Splits
  • Insider Activity
No Data
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.